TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Graziano, Francesco, Fischer, Nicholas W., Bagaloni, Irene, Di Bartolomeo, Maria, Lonardi, Sara, Vincenzi, Bruno, Perrone, Giuseppe, Fornaro, Lorenzo, Ongaro, Elena, Aprile, Giuseppe, Bisonni, Renato, Prisciandaro, Michele, Malkin, David, Gariépy, Jean, Fassan, Matteo, Loupakis, Fotios, Sarti, Donatella, Del Prete, Michela, Catalano, Vincenzo, Alessandroni, Paolo, Magnani, Mauro, Ruzzo, Annamaria
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465166/
https://ncbi.nlm.nih.gov/pubmed/32722340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082049
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars